EMIT II Plus Benzodiazepine Assay
The EMIT® II Plus Benzodiazepine Assay is intended for the qualitative and semiquantitative analysis of benzodiazepine and benzodiazepine metabolites in human urine at a cutoff value of 200 ng/mL or 300 ng/mL.
- Home
- Laboratory Diagnostics
- Drug Testing Diagnostics
- Drugs of Abuse Testing
- EMIT II Plus Benzodiazepine Assay
EMIT II Plus Benzodiazepine AssayScreen for benzodiazepines and benzodiazepine metabolites
Features & Benefits
Benzodiazepines are sedative-hypnotic drugs that are structurally similar and include widely used drugs such as chlordiazepoxide, diazepam, and oxazepam. The different benzodiazepines are absorbed at different rates, and the timing of their psychoactive effects varies with the absorption rate.
The EMIT II Plus Benzodiazepine Assay provides:
- Excellent precision—all within-lab (total) CVs ≤1.0% or less across the assay range
- Dual cutoffs available with one assay
- Ready-to-use liquid reagents, calibrators, and controls
- >80% correlation to the reference method
Applications are available for the Viva-Jr®, Viva-E®, Viva-ProE®, V-Twin® drug testing systems and AU® Series analyzers.
Technical Specifications
EMIT II Plus Benzodiazepine Assay Performance
Assay Principle | Homogeneous Enzyme Multiplied Immonoassay (EMIT) |
Cut-off | 200 ng/mL and 300 ng/mL |
Sample | Urine |
Reagent Stability | Unopened until expiration date; Onboard instrument: up to 4 weeks |
Calibration Frequency | As indicated by control results |
Did this information help you?
Thank you.
Would you like to provide detailed feedback?
125 / 125
